AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed [CNBC]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: CNBC
In this article AstraZeneca 's stock jumped as much as 4% after Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift in sentiment, given limited conviction in the IL-33 mechanism following prior IL-33 failures from Sanofi and Roche ,” said Jefferies analysts. Tozorakimab and rival drugs belong to a class of treatments called monoclonal antibodies. They work ?by suppressing the action ?of the protein interleukin-33 (IL-33) and can reduce inflammation. London-listed shares were last seen up 3.5% in midday trading, contrasting with the UK's FTSE 100 index which fell 0.6%. This is a breaking news story. Please refresh for updates.
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi gains EU approval recommendation for Scarlisa subcutaneous version [Seeking Alpha]Seeking Alpha
- AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed [MSNBC.com]MSNBC.com
- EU regulator backs Sanofi's injectable version of blood cancer drug [Yahoo! Finance]Yahoo! Finance
- Novo's FDA voucher victory; biotech's rigid glass ceiling [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myelomaGlobeNewswire
SNY
Sec Filings
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- 3/4/26 - Form 6-K
- SNY's page on the SEC website